The University of Southampton
University of Southampton Institutional Repository

FcγR requirements leading to successful immunotherapy

FcγR requirements leading to successful immunotherapy
FcγR requirements leading to successful immunotherapy
Monoclonal antibody (mAb) immunotherapy is currently experiencing an unprecedented amount of success, delivering blockbuster sales for the pharmaceutical industry. Having experienced several false dawns and overcoming technical issues which limited progress, we are now entering a golden period where mAbs are becoming a mainstay of treatment regimes for diseases ranging from cancer to autoimmunity. In this review, we discuss how these mAbs are most likely working and focus in particular on the key receptors that they interact with to precipitate their therapeutic effects. Although their targets may vary, their engagement with Fcγ receptors (FcγRs) on numerous immune effector cells is almost universal, and here we review their roles in delivering successful immunotherapy.
0105-2896
104-122
Dahal, L.
1e993a7a-b007-4187-82ea-e28dd3920b66
Roghanian, A.
e2b032c2-60a0-4522-a3d8-56a768792f36
Beers, S.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Cragg, M.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Dahal, L.
1e993a7a-b007-4187-82ea-e28dd3920b66
Roghanian, A.
e2b032c2-60a0-4522-a3d8-56a768792f36
Beers, S.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Cragg, M.
ec97f80e-f3c8-49b7-a960-20dff648b78c

Dahal, L., Roghanian, A., Beers, S. and Cragg, M. (2015) FcγR requirements leading to successful immunotherapy. [in special issue: Fc Receptors] Immunological Reviews, 268 (1), 104-122. (doi:10.1111/imr.12342). (PMID:26497516 )

Record type: Article

Abstract

Monoclonal antibody (mAb) immunotherapy is currently experiencing an unprecedented amount of success, delivering blockbuster sales for the pharmaceutical industry. Having experienced several false dawns and overcoming technical issues which limited progress, we are now entering a golden period where mAbs are becoming a mainstay of treatment regimes for diseases ranging from cancer to autoimmunity. In this review, we discuss how these mAbs are most likely working and focus in particular on the key receptors that they interact with to precipitate their therapeutic effects. Although their targets may vary, their engagement with Fcγ receptors (FcγRs) on numerous immune effector cells is almost universal, and here we review their roles in delivering successful immunotherapy.

Full text not available from this repository.

More information

e-pub ahead of print date: 26 October 2015
Published date: November 2015
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 390361
URI: http://eprints.soton.ac.uk/id/eprint/390361
ISSN: 0105-2896
PURE UUID: 64dea7ac-0e25-41d8-88c6-1a43ce3bc90e
ORCID for A. Roghanian: ORCID iD orcid.org/0000-0003-1316-4218
ORCID for S. Beers: ORCID iD orcid.org/0000-0002-3765-3342
ORCID for M. Cragg: ORCID iD orcid.org/0000-0003-2077-089X

Catalogue record

Date deposited: 24 Mar 2016 14:43
Last modified: 18 Feb 2021 17:13

Export record

Altmetrics

Contributors

Author: L. Dahal
Author: A. Roghanian ORCID iD
Author: S. Beers ORCID iD
Author: M. Cragg ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×